UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

□ QUARTERLY REPORT PURSUANT TO SI	ECTION 13 OR 15(d) OF THE SE	CCURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022	2	
☐ TRANSITION REPORT PURSUANT TO SE	ECTION 13 OR 15(d) OF THE SE	CURITIES EXCHANGE ACT OF 1934
For the transition period from to		
	Commission File No. 3	333-188920
	SCOUTCAM	I INC.
-	(Exact name of registrant as spe	
Nevada		47-4257143
(State or other jurisdictio		(I.R.S. Employer
of incorporation or organizat	tion)	Identification No.)
Suite 7A, Industrial Par	k	
P.O. Box 3030, Omer, Isr	ael	8496500
(Address of Principal Executive	Offices)	(Zip Code)
	+972 73 370-40	591
-	(Registrant's telephone number,	
(Former na	me, former address and former fisca	l year, if changed since last report)
Securities registered pursuant to Section 12(b) of the	A at:	
Securities registered pursuant to Section 12(0) of the	Act.	
Title of each class	Trading Symbol(s)	Name of exchange on which registered
Title of each class N/A	Trading Symbol(s) N/A	Name of exchange on which registered N/A
N/A Indicate by check mark whether the registrant (1) ha	N/A as filed all reports required to be file	
N/A Indicate by check mark whether the registrant (1) ha preceding 12 months (or for such shorter period that 90 days. Yes ⋈ No □ Indicate by check mark whether the registrant has si	N/A as filed all reports required to be file the registrant was required to file su ubmitted electronically every Intera-	N/A d by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
N/A Indicate by check mark whether the registrant (1) ha preceding 12 months (or for such shorter period that 90 days. Yes ⊠ No □ Indicate by check mark whether the registrant has si S-T (§ 232.405 of this chapter) during the preceding Indicate by check mark whether the registrant is a lateral transfer of the second of	N/A as filed all reports required to be file the registrant was required to file so ubmitted electronically every Intera 12 months (or for such shorter perio arge accelerated filer, an accelerated	N/A d by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the ach reports), and (2) has been subject to such filing requirements for the past etive Data File required to be submitted pursuant to Rule 405 of Regulation
N/A Indicate by check mark whether the registrant (1) ha preceding 12 months (or for such shorter period that 90 days. Yes ⋈ No □ Indicate by check mark whether the registrant has sr S-T (§ 232.405 of this chapter) during the preceding Indicate by check mark whether the registrant is a largrowth company. See the definitions of "large accel	N/A as filed all reports required to be file the registrant was required to file so ubmitted electronically every Intera 12 months (or for such shorter perio arge accelerated filer, an accelerated	N/A d by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the ich reports), and (2) has been subject to such filing requirements for the past ctive Data File required to be submitted pursuant to Rule 405 of Regulation in that the registrant was required to submit such files). Yes ⊠ No □ If filer, a non-accelerated filer, a smaller reporting company, or an emerging
N/A Indicate by check mark whether the registrant (1) ha preceding 12 months (or for such shorter period that 90 days. Yes ⋈ No ☐ Indicate by check mark whether the registrant has start (§ 232.405 of this chapter) during the preceding Indicate by check mark whether the registrant is a largrowth company. See the definitions of "large accel of the Exchange Act. ☐ Large accelerated filer ☐ Non-accelerated filer	N/A as filed all reports required to be file the registrant was required to file submitted electronically every Intera- 12 months (or for such shorter period arge accelerated filer, an accelerated erated filer, "submitted electronically every Intera- 12 months (or for such shorter period arge accelerated filer, an accelerated filer, "submitted filer," accelerated filer, "submitted filer, "submi	N/A d by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the ach reports), and (2) has been subject to such filing requirements for the past ctive Data File required to be submitted pursuant to Rule 405 of Regulation and that the registrant was required to submit such files). Yes ☒ No ☐ If filer, a non-accelerated filer, a smaller reporting company, or an emerging maller reporting company," and "emerging growth company" in Rule 12b-2 Accelerated filer Smaller reporting company Emerging growth company to use the extended transition period for complying with any new or revised
N/A Indicate by check mark whether the registrant (1) ha preceding 12 months (or for such shorter period that 90 days. Yes ⋈ No ☐ Indicate by check mark whether the registrant has st S-T (§ 232.405 of this chapter) during the preceding Indicate by check mark whether the registrant is a largowth company. See the definitions of "large accele of the Exchange Act. ☐ Large accelerated filer ☐ Non-accelerated filer If an emerging growth company, indicate by check in the preceding service of the text of th	N/A as filed all reports required to be file the registrant was required to file su ubmitted electronically every Intera- 12 months (or for such shorter perio- arge accelerated filer, an accelerated lerated filer," "accelerated filer," "su	N/A d by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the ich reports), and (2) has been subject to such filing requirements for the past ctive Data File required to be submitted pursuant to Rule 405 of Regulation of that the registrant was required to submit such files). Yes ☒ No ☐ If filer, a non-accelerated filer, a smaller reporting company, or an emerging naller reporting company," and "emerging growth company" in Rule 12b-2 Accelerated filer Smaller reporting company Emerging growth company to use the extended transition period for complying with any new or revised □
N/A Indicate by check mark whether the registrant (1) has preceding 12 months (or for such shorter period that 90 days. Yes ⋈ No □ Indicate by check mark whether the registrant has st S-T (§ 232.405 of this chapter) during the preceding Indicate by check mark whether the registrant is a largrowth company. See the definitions of "large accele of the Exchange Act. □ Large accelerated filer ⋈ Non-accelerated filer If an emerging growth company, indicate by check in financial accounting standards provided pursuant to	N/A as filed all reports required to be file the registrant was required to file su ubmitted electronically every Intera- 12 months (or for such shorter perion arge accelerated filer, an accelerated terated filer," "accelerated filer," "su mark if the registrant has elected not Section 13(a) of the Exchange Act. I tell company (as defined in Rule 12b)	N/A d by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the ich reports), and (2) has been subject to such filing requirements for the past ctive Data File required to be submitted pursuant to Rule 405 of Regulation of that the registrant was required to submit such files). Yes ⋈ No □ If filer, a non-accelerated filer, a smaller reporting company, or an emerging naller reporting company," and "emerging growth company" in Rule 12b-2 Accelerated filer Smaller reporting company Emerging growth company to use the extended transition period for complying with any new or revised □ a-2 of the Exchange Act). Yes □ No ⋈
N/A Indicate by check mark whether the registrant (1) he preceding 12 months (or for such shorter period that 90 days. Yes ⋈ No □ Indicate by check mark whether the registrant has st S-T (§ 232.405 of this chapter) during the preceding Indicate by check mark whether the registrant is a legrowth company. See the definitions of "large accelof the Exchange Act. □ Large accelerated filer ⋈ Non-accelerated filer If an emerging growth company, indicate by check in financial accounting standards provided pursuant to Indicate by check mark whether the registrant is a sh As of August 11, 2022, the registrant had 7,121,737	N/A as filed all reports required to be file the registrant was required to file su ubmitted electronically every Intera- 12 months (or for such shorter perio arge accelerated filer, an accelerated erated filer," "accelerated filer," "su mark if the registrant has elected not Section 13(a) of the Exchange Act. I tell company (as defined in Rule 12b shares of common stock, par value s wise indicated, the terms "ScoutCa	N/A d by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the ich reports), and (2) has been subject to such filing requirements for the past ctive Data File required to be submitted pursuant to Rule 405 of Regulation of that the registrant was required to submit such files). Yes ⋈ No □ If filer, a non-accelerated filer, a smaller reporting company, or an emerging naller reporting company," and "emerging growth company" in Rule 12b-2 Accelerated filer Smaller reporting company Emerging growth company to use the extended transition period for complying with any new or revised □ a-2 of the Exchange Act). Yes □ No ⋈

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

		Page
Caution	nary Note Regarding Forward-Looking Statements	3
PART	1-FINANCIAL INFORMATION	
Item 1.	Consolidated Financial Statements (unaudited)	4
	Consolidated Balance Sheets	5
	Consolidated Statements of Comprehensive Loss	7
	Statements of Stockholders' Equity	8
	Consolidated Statements of Cash Flows	10
	Notes to Consolidated Financial Statements	12
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	26
Item 4.	Control and Procedures	26
PART	II-OTHER INFORMATION	
Item 1A	A. Risk Factors	27
Item 6.	. Exhibits	27
SIGNA	ATURES	28
	- 2 -	

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere herein may address or relate to future events and expectations and as such constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2021 (filed on March 30, 2022) entitled "Risk Factors" as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

Item 1. Financial Statements

ScoutCam INC. INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2022

CONSOLIDATED SCOUTCAM INC.

	Page
Interim Condensed Consolidated Financial Statements - in US Dollars (USD) in thousands	
Interim Condensed Consolidated Balance Sheets (unaudited)	5
Interim Condensed Consolidated Statements of Operations (unaudited)	7
Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited)	8
Interim Condensed Consolidated Statements of Cash Flows (unaudited)	10
Notes to the Interim Condensed Consolidated Financial Statements	12
- 4 -	

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2022	December 31, 2021	
	Unaudited	Audited	
	USD in tho	usands	
Assets			
CURRENT ASSETS:			
Cash and cash equivalents	7,314	8,581	
Short terms deposits	9,536	11,013	
Accounts receivable	99	8	
Inventory	609	167	
Other current assets	410	443	
	17,968	20,212	
NON-CURRENT ASSETS:			
Contract fulfillment assets	1,615	1,675	
Property and equipment, net	720	781	
Operating lease right-of-use assets	431	482	
Severance pay asset	329	396	
	3,095	3,334	
TOTAL ASSETS	21,063	23,546	

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

${\tt INTERIM}\ {\tt CONDENSED}\ {\tt CONSOLIDATED}\ {\tt BALANCE}\ {\tt SHEETS}\ ({\tt CONTINUED})$

	June 30, 2022	December 31, 2021
-	Unaudited	Audited
-	USD in tho	usands
Liabilities and shareholders' equity		
• •		
CURRENT LIABILITIES:		
Accounts payables	309	103
Contract liabilities - short term	1,426	346
Operating lease liabilities - short term	228	256
Accrued compensation expenses	376	355
Related parties	22	39
Other accrued expenses	295	210
	2,656	1,309
NON-CURRENT LIABILITIES:		
Contract liabilities - long term	2,429	2,074
Operating lease liabilities - long term	137	203
Liability for severance pay	328	344
	2,894	2,621
TOTAL LIABILITIES	5,550	3,930
SHAREHOLDERS' EQUITY:		
Common stock, \$0.001 par value; 300,000,000 shares authorized as of June 30, 2022 and		
December 31, 2021, 7,121,737 shares issued and outstanding as of June 30, 2022 and December		
31, 2021	7	7
Additional paid-in capital	36,360	34,903
Accumulated deficit	(20,854)	(15,294)
TOTAL SHAREHOLDERS' EQUITY	15,513	19,616
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	21.063	23,546
_	21,003	25,5 10

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Six months June 30		Three months June 30	
	2022	2021	2022	2021
		Unaudited	l	
	1	USD in thousands (except	t per share data)	
Revenues	372	298	370	274
Cost of revenues	849	610	561	407
Gross Loss	(477)	(312)	(191)	(133)
Research and development expenses	1,975	643	1,021	362
Sales and marketing expenses	446	404	203	207
General and administrative expenses	2,452	2,328	1,166	1,395
Operating loss	(5,350)	(3,687)	(2,581)	(2,097)
Other income	15	-	7	-
Financing income (expenses), net	(225)	(7)	(198)	9
Net Loss	(5,560)	(3,694)	(2,772)	(2,088)
Net loss per ordinary share (basic and diluted, USD)	(0.78)	(0.67)	(0.39)	(0.31)
Weighted average ordinary shares (basic and diluted, in thousands)	7,122	5,480	7,122	6,724
	- 7 -			

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

Six Months Ended June 30, 2022 (Unaudited)

	Ordinary sha	res	Additional paid-in	Accumulated	Total Shareholders'	
	Number	Amount	capital	deficit	Equity	
	In thousands	USD in thousands		ousands		
Balance at January 1, 2022	7,122	7	34,903	(15,294)	19,616	
Stock based compensation	-	-	1,457	-	1,457	
Net loss	-	-	-	(5,560)	(5,560)	
Balance at June 30, 2022	7,122	7	36,360	(20,854)	15,513	

Three Months Ended June 30, 2022 (Unaudited)

	Ordinary shares		Additional Accumulated		Total Shareholders'	
	Number	Amount	capital	deficit	Equity	
	In thousands	In thousands USD in thousands		ousands	<u> </u>	
Balance at April 1, 2022	7,122	7	35,675	(18,082)	17,600	
Stock based compensation	-	-	685	-	685	
Net loss	-	-	-	(2,772)	(2,772)	
Balance at June 30, 2022	7,122	7	36,360	(20,854)	15,513	

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

Six Months Ended June 30, 2021 (Unaudited)

	Ordinary sh	ares	Additional paid-in	Accumulated	Total Shareholders'	
	Number	Amount	capital	deficit	equity	
	In thousands		USD in thousands			
Balance at January 1, 2021	4,084	4	10,267	(6,307)	3,964	
Issuance of shares and warrants	2,469	2	19,116	-	19,118	
Stock based compensation	-	-	635	-	635	
Exercise of warrants	375	1	2,458	-	2,459	
Net loss				(3,694)	(3,694)	
Balance at June 30, 2021	6,928	7	32,476	(10,001)	22,482	

Three Months Ended June 30, 2021 (Unaudited)

	Ordinary sh	ares	Additional paid-in	Accumulated	Total Shareholders'
	Number	Amount	capital	deficit	Equity
	In thousands		USD in thousands		
Balance at April 1, 2021	6,699	7	30,242	(7,913)	22,336
Exercise of warrants	229	*	1,678	-	1,678
Stock based compensation	-	-	556	-	556
Net loss	-	-	-	(2,088)	(2,088)
Balance at June 30, 2021	6,928	7	32,476	(10,001)	22,482

^{*} Represents an amount less than \$1 thousand

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months en June 30,	ded	Three months June 30,	
•	2022	2021	2022	2021
·		Unaudite	d	
-		USD in thous	sands	
CASH FLOWS FROM OPERATING ACTIVITIES:				
Net loss	(5,560)	(3,694)	(2,772)	(2,088)
Adjustments to reconcile net loss to net cash used in				
operations:				
Depreciation	103	39	53	22
Changes in severance pay asset, net	51	(56)	51	(56)
Share based compensation	1,457	635	685	556
Profit from exchange differences from operating lease liability Loss (Profit) from exchange differences on cash and cash	(50)	-	(40)	-
equivalents	327	(4)	286	(16)
Interest income in respect of deposits	(23)	-	(10)	-
CHANGES IN OPERATING ASSET AND LIABILITY ITEMS:				
Increase in accounts receivable	(91)	(43)	(85)	(49)
Decrease (increase) in inventory	(442)	99	(419)	200
Decrease in operating lease liability	(125)	-	(109)	
Decrease in ROU asset	132		113	-
Increase (decrease) in related parties	(17)	60	-	14
Decrease (increase) in other current assets	33	(509)	6	(404)
Increase (decrease) in account payables	206	224	82	(189)
Decrease (increase) in contract fulfillment assets	60	(380)	60	(140)
Increase (decrease) in contract liabilities	1,435	537	(181)	(126)
Increase in accrued compensation expenses	21	60	1	140
Increase (decrease) in other accrued expenses	85	(22)	105	(144)
Net cash flows used in operating activities	(2,398)	(3,054)	(2,174)	(2,280)
CASH FLOWS FROM INVESTING ACTIVITIES:				
Purchase of property and equipment	(42)	(170)	(18)	(53)
Withdrawal of short terms deposits	5,000	_	5,000	-
Investment in short term deposits	(3,500)	_	(3,500)	-
Net cash flows provided by (used in) investing activities	1,458	(170)	1,482	(53)
CASH FLOWS FROM FINANCING ACTIVITIES:				
Proceeds from exercise of warrants		2.504		1.723
Proceeds from issuance of shares and warrants	_	19,118	_	9,618
Net cash flows provided by financing activities		21,622		11,341
INCREASE (DECREASE) IN CASH AND CASH				
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(940)	18,398	(692)	9,008
PROFIT (LOSS) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	(327)	4	(286)	16
BALANCE OF CASH AND CASH EQUIVALENTS AT	(321)	7	(200)	10
THE BEGINNING OF THE PERIOD	8,581	3,373	8,292	12,751
BALANCE OF CASH AND CASH EQUIVALENTS AT	0,501	3,313	0,272	12,731
THE END OF THE PERIOD	7,314	21,775	7,314	21,775
-	- 10 -			

Non cash activities -

	Six months ended June 30,		Three months June 30	
	2022	2021	2022	2021
	Unaudited			
	USD in thousands			
Issuance expenses	-	45	-	45
Right-of-use assets obtained in exchange for operating lease				
liabilities	81	359	35	133
The accompanying notes are an integral	l part of these interim con	ndensed consolidated fin	nancial statements.	

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL:

a. ScoutCam Inc. (the "Company"), formerly known as Intellisense Solutions Inc., ("Intellisense"), was incorporated under the laws of the State of Nevada on March 22, 2013. Prior to the closing of the Exchange Agreement (as defined below), the Company was a non-operating "shell company".

The Company's wholly owned subsidiary, ScoutCam Ltd. ("ScoutCam"), was formed in the State of Israel on January 3, 2019, as a wholly-owned subsidiary of Medigus Ltd. ("Medigus"), an Israeli company traded on the Nasdaq Capital Market, and commenced operations on March 1, 2019.

In December 2019, Medigus and ScoutCam consummated an asset transfer agreement, under which Medigus transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business to ScoutCam.

On December 30, 2019, Intellisense and Medigus consummated a securities exchange agreement (the "Exchange Agreement"), pursuant to which Medigus delivered 100% of its holdings in ScoutCam to Intellisense in exchange for shares of Intellisense's common stock representing 60% of the issued and outstanding share capital of Intellisense immediately upon the consummation of the Exchange Agreement.

As of June 30, 2022, Medigus beneficially owned 27.01% of the Company's outstanding common stock.

The Company, through ScoutCam, provides image-based platforms. Through the use of its proprietary visualization technology, ScoutCam offers solutions across predictive maintenance and condition-based monitoring markets, in sectors such as energy, automotive and aviation. ScoutCam's solutions are based on small and highly resilient cameras, specialized AI analysis and supplementary technologies.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continued):

- b. On August 9, 2021, the Company amended its Articles of Incorporation to effect a nine-to-one reverse stock split of its outstanding Common Stock. As a result of the reverse stock split, every nine shares of the Company's outstanding Common Stock were combined and reclassified into one share of the Company's Common Stock. No fractional shares were issued in connection with or following the reverse split. The amount of authorized capital of the Company's Common Stock and par value of such shares remained unchanged. All share, stock option and per share information in these interim consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis.
- c. Since incorporation of ScoutCam and through June 30, 2022, the Company accumulated a deficit of approximately \$20,854 thousand and its activities have been funded mainly by its shareholders. The Company's management believes the Company' cash and cash resources as of June 30, 2022 will enable the Company to fund its operating plan for more than 12 months from the date of issuance of these financial statements. The Company expects to continue to incur significant research and development expenses and other costs related to its ongoing operations and, as a result, will need to obtain additional funding in order to continue its future operations.
- d. In early 2020, the World Health Organization declared the rapidly spreading coronavirus disease (COVID19) outbreak a pandemic. This pandemic has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Company considered the impact of COVID-19 on its operations and determined that there were no material adverse impacts on the Company's results of operations and financial position as of June 30, 2022. These estimates may change, as new events occur and additional information is obtained.

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

a. Unaudited Interim Financial Statements

The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Group's Annual Report on Form 10-K for the year ended December 31, 2021.

b. Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

c. Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment, stock based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued):

d. Significant Accounting Policies

The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.

As described therein, to the extent development services are not distinct from the performance obligation relating to the subsequent production phase, revenue from these services is deferred until commencement of the production phase. Further to the inception of the production phase (refer to Note 5), the Company recognizes deferred development services over the expected term of production.

e. Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Group's condensed consolidated financial statements.

NOTE 3 – LEASES:

On June 30, 2022, the Group's ROU assets and lease liabilities for operating leases totaled \$431 thousands and \$365 thousand, respectively.

In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning on January 1, 2021. ScoutCam holds the right to terminate the lease agreement after 24 months. In March 2021, ScoutCam entered into a lease agreement for additional office space in Omer, Israel. The agreement is until December 31, 2023. ScoutCam holds the right to terminate these agreements by December 31, 2022. Monthly lease payments under the agreements are approximately \$12 thousand.

Lease expenses recorded in the interim consolidated statements of operations were \$136 thousand for the six months ended June 30, 2022.

ScoutCam subleases part of the office space to a third party for approximately \$3 thousand for month.

Supplemental cash flow information related to operating leases was as follows:

	30, 2022
	USD in thousands
Cash payments for operating leases	136
Total lease expenses	136

As of June 30, 2022, the Company's operating leases had a weighted average remaining lease term of 0.71 years and a weighted average discount rate of 6%. Future lease payments under operating leases as of June 30, 2022 were as follows:

	Operating leases
	USD in thousands
Remainder of 2022	122
2023	222
2024	41
Total future lease payments	385
Less imputed interest	(20)
Total lease liability balance	365

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY:

Warrants:

As of June 30, 2022, the Company had the following outstanding warrants to purchase common stock:

<u>W</u> arrant	Issuance Date	Expiration Date	Exercise Price Per Share (\$)	Number of Shares of common stock Underlying Warrants
Warrant March 2021	March 29, 2021	March 31, 2026	10.350	2,469,156
				2,469,156

In addition, if ScoutCam achieves an aggregate amount of \$33 million in sales within the first three years immediately after the Exchange Agreement, the Company will issue to Medigus 298,722 shares of the Company's common stock, which represents 10% of the Company's issued and outstanding share capital as of the Exchange Agreement.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY (continued):

Share-based compensation to employees, directors and service providers:

In February 2020, the Company's Board of Directors approved the 2020 Share Incentive Plan (the "Plan"). The Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company's Board of Directors approved an increase to the Company's option pool pursuant to the Plan by an additional 64,099 shares of common stock. On June 22, 2020, the Company's Board of Directors approved an increase to the Company's option pool pursuant to the Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company's Board of Directors approved an increase to the Company's option pool pursuant to the Plan by an additional 777,778 shares of common stock.

The Plan is designed to enable the Company to grant options to purchase shares of common stock and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3 (i) of the Israeli Tax Ordinance.

Stock option activity

During the six months ended June 30, 2022, the Company granted 53,000 options pursuant to the Plan.

The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option pricing model, using the following assumptions:

	Six months ended June 30, 2022
Underlying value of ordinary shares (\$)	7.2
Exercise price (\$)	4.5
Expected volatility (%)	127.62%
Term of the options (years)	7
Risk-free interest rate	1.98%

The cost of the benefit embodied in the options granted during the six months ended June 30, 2022, based on their fair value as at the grant date, is estimated to be approximately \$356 thousands. These amounts will be recognized in statements of operations over the vesting period.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY (continued):

The following table summarizes stock option activity for the six months ended June 30, 2022:

For the Six months ended June 30, 2022

	ounc 50,	ounc 50, 2022		
	Amount of options	Weighted average exercise price		
		\$		
Outstanding at beginning of period	1,253,554	3.31		
Granted	53,000	4.50		
Cancelled	(37,011)	2.61		
Outstanding at end of period	1,269,543	4.14		
Vested at end of period	673,509	2.98		

Restricted stock unit ("RSU") activity

During the six months ended June 30, 2022, the Company granted 90,000 RSUs pursuant to the Plan.

Each RSU will vest based on continued service which is generally over three years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company's common stock.

The cost of the benefit embodied in the RSU granted during the six months ended June 30, 2022, based on their fair value as at the grant date, is estimated to be approximately \$648 thousands. These amounts will be recognized in statements of operations over the vesting period

The following table summarizes RSU activity for the six months ended June 30, 2022:

For the			
Six months ended			
T 20 2022			

	June 3	June 30, 2022		
	Amount of options	Weighted Average Grant Date Fair Value per Share		
Outstanding at beginning of period	_			
Granted	90,000	7.2		
Vested				
Forfeited	-	-		
Unvested and Outstanding at end of period	90,000	7.2		
on. sold and outsidening at one of period	90,000	1.2		

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY (continued):

The following table sets forth the total share-based payment expenses resulting from options granted, included in the statements of operation:

	ended June 30, 2022
	USD in thousands
Cost of revenues	48
Research and development	311
Sales and marketing	99
General and administrative	999
Total expenses	1,457

NOTE 5 – REVENUES:

Contract fulfillment assets and Contract liabilities:

The Company's contract fulfillment assets and contract liabilities as of June 30, 2022 and December 31, 2021 were as follows:

	June 30,	December 31,		
	2022	2021		
	USD in	USD in thousands		
Contract fulfillment assets	1,615	1,675		
Contract liabilities	3,855	2,420		

Contract liabilities include advance payments, which are primarily related to advanced billings for development services.

In the current quarter the Company completed the development service stage of its miniature camera solution relating these deferred development services and moved from the development stage to the production stage. As a result, the Company recognized \$106 thousands during the period, based on the expected term of the production stage.

Remaining Performance Obligations

Remaining Performance Obligations ("RPO") represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be recognized as revenue in future periods. As of June 30, 2022, the total RPO amounted to \$3,855 thousand, which the Company expects to recognize over the expected manufacturing term of the product under development.

NOTE 6 - SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 - INVENTORY:

Composed as follows:

	June 30, 2022	December 31, 2021
	USD in	thousands
Raw materials and supplies	596	99
Work in progress	13	2
Finished goods	-	66
	609	167

During the period ended June 30, 2022, no impairment occurred.

NOTE 7 – LOSS PER SHARE

Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company, by the weighted average number of ordinary shares as described below.

In computing the Company's diluted loss per share, the numerator used in the basic loss per share computation is adjusted for the dilutive effect, if any, of the Company's potential shares of common stock. The denominator for diluted loss per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period.

NOTE 8 - RELATED PARTIES

a. Balances with related parties:

•	June 30, 2022	December 31, 2021
	USD in	thousands
	•	
Directors(*)	22	-
Medigus	-	39

(*) represents directors' compensation

b. During six months ended June 30, 2022 the Company received development services from Smartec R&D Ltd., a company owned by the Company's CTO.

Total compensation during the six months ended June 30, 2022 and June 30, 2021 was approximately \$55 thousands and \$40 thousands, respectively.

NOTE 9 – SUBSEQUENT EVENTS

On July 12, 2022, the Company and the Chief Executive Officer of the Company, mutually agreed that the CEO's employment with the Company would terminate on October 18, 2022.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See "Cautionary Note Regarding Forward-Looking Statements". You should review the "Risk Factors" section of our Annual Report for the fiscal year ended December 31, 2021 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

The Company's primary business activity during last few months was enlarging its focus on R&D activities in the domain of I4.0 (including Predictive Maintenance, PdM, and Condition Based Monitoring, CBM, in sectors such as the aviation, energy and automotive). The main effect of this activity was an increase in the number of employees to enable the Company to manage the anticipated increased workload and solution development.

In addition, recently the Company completed the verification and validation (V&V) stage of its miniature camera solution with a Fortune 500 company and moved from R&D stage to production stage.

Comparison of the six months ended June 30, 2022 and 2021

The following table summarizes our results of operations for the six months period ended June 30, 2022 and 2021, together with the changes in those items in dollars and as a percentage:

	Six months ended June 30,		
	2022	2021	% Change
Revenues	372,000	298,000	25%
Cost of Revenues	849,000	610,000	39%
Gross Loss	(477,000)	(312,000)	53%
Research and development expenses	1,975,000	643,000	207%
Sales and marketing expense	446,000	404,000	10%
General and administrative expenses	2,452,000	2,328,000	5%
Operating Loss	(5,350,000)	(3,687,000)	45%

Revenues

As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.

For the six months ended June 30, 2022, we generated revenues of \$372,000, an increase of \$74,000, or 25% from the six months ended June 30, 2021.

The increase in revenues was primarily due to the increase in revenue from our miniature camera solution with the Fortune 500 company due to completion R&D stage and moving to production stage. Total revenues recorded from our miniature camera solution with the Fortune 500 company during the six months ended June 30, 2022, amounted to approximately \$327,000. We did not record any revenue from our miniature camera solution with the Fortune 500 company during the six months ended June 30, 2021.

This increase in revenues was partly offset by the following:

- Total revenues recorded from A.M. Surgical during the six months ended June 30, 2021, amounted to approximately \$200,000. We did not record any revenue from A.M. Surgical during the six months ended June 30, 2022.
- the decrease of \$53,000 due to an overall decrease in the sales of the Company's component products to occasional customers.

Cost of Revenues

Cost of revenue is primarily comprised of cost of personnel including warehouse personnel costs, inventory write-downs, certain allocated facilities and expenses associated with logistics and quality control.

Cost of revenues for the six months ended June 30, 2022 was \$849,000, an increase of \$239,000, or 39%, compared to cost of revenues of \$610,000 for the six months ended June 30, 2021. The increase was primarily due to an increase in materials as a result of an increase in revenues, an increase in payroll expenses due to stock-based compensation and due to the transition from the R&D stage to the production stage as described on "Overview" and increase in facility costs due to a lease for additional office space.

Gross Loss

Gross loss for the six months ended June 30, 2022 was \$477,000, an increase of \$165,000, or 53%, compared to gross loss of \$312,000 for the six months ended June 30, 2021.

The increase was primarily due to increase in cost of revenues partially offset by an increase in revenue as described above.

Research and Development Expenses

Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation and other supplies. We expense research and development costs as incurred.

Research and development expenses for the six months ended June 30, 2022 were \$1,975,000, an increase of \$1,332,000, or 207%, compared to \$643,000 for the six months ended June 30, 2021.

The increase was primarily due to an increase in payroll expenses (including stock-based compensation), materials and subcontractors, and because we have recently begun examining additional applications for our micro ScoutCamTM portfolio outside of the medical, defense and aerospace fields, including in sectors such as automotive, industrial non-destructing-testing industries, automotive and energy and increase in facility costs due to a lease for additional office space.

In addition, there was an increase in R&D payroll expenses in first half of 2022 due to the fact that during the first half of 2021 a part of our payroll expenses was capitalized to contract fulfillment asset and was not recognized as expenses in profit and loss.

We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the I4.0 domain.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of personnel costs, consulting services, promotional materials, demonstration equipment and certain allocated facility infrastructure costs.

Sales and marketing expenses for the six months ended June 30, 2022 were \$446,000, an increase of \$42,000, or 10%, compared to \$404,000 for the six months ended June 30, 2021.

The increase was primarily due to an increase in payroll expenses (including stock-based compensation) due to the recruitment of a VP Business Development in Industry 4.0.

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts.

General and Administrative Expenses

General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs, as well as professional fees for legal, patent, consulting, investor, and public relations, accounting, auditing, tax services and insurance costs.

General and Administrative expenses for the six months ended June 30, 2022 were \$2,452,000, an increase of \$124,000, or 5%, compared to \$2,328,000 for the six months ended June 30, 2021.

The increase was primarily due to an increase in share based compensation due to new options and RSUs grants, partially offset by a decrease in IP expenses.

Operating loss

We incurred an operating loss of \$5,350,000 for the six months ended June 30, 2022, an increase of \$1,663,000, or 45%, compared to operating loss of \$3,687,000 for the six months ended June 30, 2021.

The increase in operating loss was primarily due to increases in expenses related to general and administrative, research and development and sales and marketing, as described above.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):

	Six month ended	Six month ended June 30,	
	2022	2021	
Cash used in Operating Activity	(2,398,000)	(3,054,000)	
Cash provided by (used in) Investing Activity	1,458,000	(170,000)	
Cash provided by Financing Activity	-	21,622,000	

Operating Activities

Our primary uses of cash from operating activities have been for headcount-related expenditures, research and development costs, manufacturing costs, marketing and promotional expenses, professional services cost and costs related to our facilities. Our cash flows from operating activities will continue to be affected due to the expected increase of spending on our business and our working capital requirements.

During the six months ended June 30, 2022, cash used in operating activities was \$2.4 million, consisting of net loss of \$5.6 million, partially offset by a non-cash benefit of \$1.5 million, a favorable net change in operating assets and liabilities of \$1.3 million and loss from exchange differences on cash and cash equivalents of \$0.3 million. Our non-cash benefit consisted primarily of non-cash charges of \$1.5 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in contract liability of \$1.4 million.

During the six months ended June 30, 2021, cash used in operating activities was \$3.1 million, consisting of net loss of \$3.7 million partially offset by a non-cash benefit of \$0.6 million. Our non-cash benefit consisted primarily of non-cash charges of \$0.6 million for stock-based compensation.

Investing Activities

For the six months ended June 30, 2022, net cash flows provided by investing activities was \$1,458,000, due to change of \$1,500,000 in short terms deposits partially offset by the purchase of property and equipment.

For the six months ended June 30, 2021, net cash flows used in investing activities was \$170,000, due to the purchase of property and equipment.

Financing Activities

For the six months ended June 30, 2021, net cash flows provided by financing activities was \$21.6 million, due to proceeds from the issuance of shares and warrants equivalent to approximately \$19.1 million and proceeds from exercise from warrants of approximately \$2.5 million.

Comparison of the three months ended June 30, 2022 and 2021

The following table summarizes our results of operations for the three months period ended June 30, 2022, and 2021, together with the changes in those items in dollars and as a percentage:

	Three months ended June 30,		
	2022	2021	% Change
Revenues	370,000	274,000	35%
Cost of Revenues	561,000	407,000	38%
Gross Loss	(191,000)	(133,000)	44%
Research and development expenses	1,021,000	362,000	182%
Sales and marketing expense	203,000	207,000	(2)%
General and administrative expenses	1,166,000	1,395,000	(16)%
Operating Loss	(2,581,000)	(2,097,000)	23%

Revenues

For the three months ended June 30, 2022, we generated revenues of \$370,000, an increase of \$96,000, or 35%, from the three months ended June 30, 2021

The increase in revenues was primarily due to the increase in revenue from our miniature camera solution with the Fortune 500 company due to completion R&D stage and moving to production stage. Total revenues recorded from our miniature camera solution with the Fortune 500 company during the six months ended June 30, 2022, amounted to approximately \$327,000. We did not record any revenue from our miniature camera solution with the Fortune 500 company during the three months ended June 30, 2021.

This increase in revenues was partly offset by the following:

- Total revenues recorded from A.M. Surgical during the six months ended June 30, 2021, amounted to approximately \$200,000. We did not record any revenue from A.M. Surgical during the three months ended June 30, 2022.
- the decrease of \$31,000 due to an overall decrease in the sales of the Company's component products to occasional customers.

Cost of Revenues

Cost of revenue is primarily comprised of cost of personnel including warehouse personnel costs, inventory write-downs, certain allocated facilities and expenses associated with logistics and quality control.

Cost of revenues for the three months ended June 30, 2022 was \$561,000, an increase of \$154,000, or 38%, compared to cost of revenues of \$407,000 for the three months ended June 30, 2021.

The increase was primarily due to an increase in materials as a result of an increase in revenues, an increase in payroll expenses due to stock-based compensation and due to the transition from the R&D stage to the production stage as described on "Overview" and increase in facility costs due to a lease for additional office space.

Gross Loss

Gross loss for the three months ended June 30, 2022 was \$191,000, an increase of \$58,000, or 44%, compared to gross loss of \$133,000 for the three months ended June 30, 2021.

The increase was primarily due to increase in cost of revenues partially offset by an increase in revenue as described above.

Research and Development Expenses

Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting and professional fees related to research and development activities, prototype materials, facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation and other supplies. We expense research and development costs as incurred.

Research and development expenses for the three months ended June 30, 2022 were \$1,021,000, an increase of \$659,000, or 182%, compared to \$362,000 for the three months ended June 30, 2021.

The increase was primarily due to an increase in payroll expenses (including stock-based compensation), materials and subcontractors, and because we have recently begun examining additional applications for our micro ScoutCamTM portfolio outside of the medical, defense and aerospace fields, including in sectors such as automotive, industrial non-destructing-testing industries, automotive and energy and increase in facility costs due to a lease for additional office space.

We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the I4.0 domain.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of personnel costs, consulting services, promotional materials, demonstration equipment and certain allocated facility infrastructure costs.

Sales and marketing expenses for the three months ended June 30, 2022 were \$203,000, a decrease of \$4,000, or 2%, compared to \$207,000 for the three months ended June 30, 2021.

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts.

General and Administrative Expenses

General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs, as well as professional fees for legal, patent, consulting, investor, and public relations, accounting, auditing, tax services and insurance costs.

General and Administrative expenses for the three months ended June 30, 2022 were \$1,166,000, a decrease of \$229,000, or 16%, compared to \$1,395,000 for the three months ended June 30, 2021.

The decrease was primarily due to a decrease in IP expenses.

Operating loss

We incurred an operating loss of \$2,581,000 for the three months ended June 30, 2022, an increase of \$484,000, or 23%, compared to operating loss of \$2,097,000 for the three months ended June 30, 2021.

The increase in operating loss was primarily due to increases in expenses related to general and administrative, research and development and sales and marketing, as described above.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):

	Three month ended	Three month ended June 30,	
	2022	2021	
Cash used in Operating Activity	(2,174,000)	(2,280,000)	
Cash provided by (used in) Investing Activity	1,482,000	(53,000)	
Cash provided by Financing Activity	-	11,341,000	

Operating Activities

Our primary use of cash from operating activities have been for headcount-related expenditures, research and development costs, manufacturing costs, marketing and promotional expenses, professional services cost and costs related to our facilities. Our cash flows from operating activities will continue to be affected due to the expected increase of spending on our business and our working capital requirements.

During the three months ended June 30, 2022, cash used in operating activities was \$2.2 million, consisting of net loss of \$2.8 million and an unfavorable net change in operating assets and liabilities of \$0.4 million partially offset by a non-cash benefit of \$0.7 million, and loss from exchange differences on cash and cash equivalents of \$0.3 million. Our non-cash benefit consisted primarily of non-cash charges of \$0.7 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in inventory of \$0.4 million.

Investing Activities

For the three months ended June 30, 2022, net cash flows provided by investing activities was \$1,482,000, due to change of \$1,500,000 in short terms deposits partially offset by the purchase of property and equipment.

For the three months ended June 30, 2021, net cash flows used in investing activities was \$53,000, due to the purchase of property and equipment.

Financing Activities

For the three months ended June 30, 2021, net cash flows provided by financing activities was \$11.3 million, due to proceeds from the issuance of shares and warrants equivalent to approximately \$9.6 million and proceeds from exercise from warrants of approximately \$1.7 million.

Additional Cash Requirements

We plan to continue to invest for long-term growth, and therefore we expect that our expenses will increase. We currently believe that our existing cash and cash equivalents and short-term deposits will be sufficient to meet our anticipated cash needs for at least the next 12 months. We expect our expenses will increase in connection with our ongoing activities, particularly as we continue the research and development and the scale up process of our 14.0 solutions. We expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We may raise these funds through equity financing, debt financing or other sources, which may result in further dilution in the equity ownership of our common stock. There is no assurance that we will be able to maintain operations at a level sufficient for investors to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan, we will, most likely, continue to be unprofitable for the foreseeable future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

Liquidity and Capital Resources

As of June 30, 2022, we had cash and cash equivalents of \$7.3 million and \$9.5 million of short-term deposits compared to cash and cash equivalents \$8.6 million and \$11 million of short-term deposits as of December 31, 2021. In addition, as of June 30, 2022 we incurred an accumulated deficit of approximately \$20.9 million, compared to \$15.3 million as of December 31, 2021.

Our primary sources of liquidity to date have been from fund raising and warrant exercises.

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Exchange Act Rule 13a-15(e). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

No change in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(e), occurred during the fiscal quarter ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.

ITEM 1A. RISK FACTORS.

There have been no material changes from the information set forth in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31,2021 as filed with the SEC on March 30, 2022.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

There have been no unregistered sales of equity securities in addition to the sales provided under Form 8-K as filed with the SEC during the recent fiscal quarter ended June 30, 2022.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS.

(a) The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.

Exhibit Number	Description			
3.1.1	Amended and Restarted Articles of Incorporation, effective as of August 9, 2021 (incorporated by reference to Exhibit 3.1.4 to our Quarterly Report on Form 10-Q filed with the SEC on August 12,2021)			
3.2.1	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2.2 to our Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021).			
31.1*	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act			
31.2*	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act			
32.1**	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002			
32.2**	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002			
101.INS	Inline XBRL Instance Document			
101.INS	Inline XBRL Taxonomy Extension Schema Document			
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document			
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document			
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document			
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document			
104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)			
*	Filed herewith.			
**	Furnished herewith.			
- 27 -				

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 11, 2022 SCOUTCAM INC.

> /s/ Benad Goldwasser Name: Benad Goldwasser

Title: Chairman of the Board

ScoutCam Inc.

 $\begin{array}{ll} \text{By:} & \frac{\text{/s/Tanya Yosef}}{\text{Tanya Yosef}} \\ \text{Title:} & \text{Chief Financial Officer} \end{array}$

ScoutCam Inc.

- 28 -

CERTIFICATION PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Benad Goldwasser, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022 of ScoutCam Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the quarter end covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the quarter end presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the quarter end in which this report is being prepared;
- b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the quarter end covered by this report based on such evaluation; and
- d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 11, 2022

/s/ Benad Goldwasser

Benad Goldwasser Chairman of the Board Principal Executive Officer

CERTIFICATION PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Tanya Yosef, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022, of ScoutCam Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the quarter end covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the quarter end presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the quarter end in which this report is being prepared;
- b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the quarter end covered by this report based on such evaluation; and
- d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 11, 2022

/s/ Tanya Yosef
Tanya Yosef
Chief Financial Officer

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ScoutCam Inc. (the "Company") on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Benad Goldwasser, Chairman of the Board and principal executive officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Benad Goldwasser

Benad Goldwasser Chairman of the Board Principal Executive Officer ScoutCam Inc. August 11, 2022

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ScoutCam Inc. (the "Company") on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Tanya Yosef, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.